The Journal of clinical endocrinology and metabolism · 2026
Patterns of TSH test after GLP-1 RAs initiation in patients on levothyroxine: a trial emulation study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen Yishan, Du Fanxing, Singh Ospina Naykky M, Brito Juan P, Shao Hui, Liu Qing, McCoy Rozalina G, Jiao Tianze
Аннотация
CONTEXT: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely prescribed for type 2 diabetes and obesity and can lead to substantial weight loss. In patients taking levothyroxine, weight loss can reduce thyroid hormone requirements and potentially associated adverse effects. Thyroid-stimulating hormone (TSH) monitoring is essential but unclear whether thyroid function is routinely reassessed after GLP-1 RAs initiation.
OBJECTIVE: Examine the changes in the timing of TSH testing after GLP-1 RAs.
DESIGN: Retrospective cohort study emulating a target trial using Medicare from January 1, 2011, to December 31, 2020. The primary analysis followed an intention-to-treat approach. Patients were matched 1:1 using propensity scores. Logistic regression models and informed by least absolute shrinkage operator variable selection were used.
SETTING: The 15% sample of U.S. Medicare fee-for-service claims data.
PATIENTS OR OTHER PARTICIPANTS: Adults aged ≥65 years with type 2 diabetes on a stable levothyroxine dose at baseline.
INTERVENTION(S): Initiation of GLP-1 RAs vs initiation/ongoing use of sodium-glucose cotransporter-2 inhibitors (SGLT-2is).
MAIN OUTCOME MEASURE(S): TSH testing during follow-up.
RESULTS: Among 5370 matched patients, the mean age was 73.2 years. 71.6% were women, and 87.1% were White. Approximately 83.0% of patients in both treatment groups receive a TSH testing within a 1-year follow-up. The mean time to TSH testing was approximately 130.5 days for both groups.
CONCLUSION: TSH testing patterns did not differ between GLP-1 RAs and SGLT-2is, despite the greater likelihood of requiring levothyroxine dose adjustment associated with weight loss seen with GLP-1 RA therapy. Given levothyroxine's widespread use, this gap suggests missed opportunities for timely and weight-responsive thyroid monitoring.
OBJECTIVE: Examine the changes in the timing of TSH testing after GLP-1 RAs.
DESIGN: Retrospective cohort study emulating a target trial using Medicare from January 1, 2011, to December 31, 2020. The primary analysis followed an intention-to-treat approach. Patients were matched 1:1 using propensity scores. Logistic regression models and informed by least absolute shrinkage operator variable selection were used.
SETTING: The 15% sample of U.S. Medicare fee-for-service claims data.
PATIENTS OR OTHER PARTICIPANTS: Adults aged ≥65 years with type 2 diabetes on a stable levothyroxine dose at baseline.
INTERVENTION(S): Initiation of GLP-1 RAs vs initiation/ongoing use of sodium-glucose cotransporter-2 inhibitors (SGLT-2is).
MAIN OUTCOME MEASURE(S): TSH testing during follow-up.
RESULTS: Among 5370 matched patients, the mean age was 73.2 years. 71.6% were women, and 87.1% were White. Approximately 83.0% of patients in both treatment groups receive a TSH testing within a 1-year follow-up. The mean time to TSH testing was approximately 130.5 days for both groups.
CONCLUSION: TSH testing patterns did not differ between GLP-1 RAs and SGLT-2is, despite the greater likelihood of requiring levothyroxine dose adjustment associated with weight loss seen with GLP-1 RA therapy. Given levothyroxine's widespread use, this gap suggests missed opportunities for timely and weight-responsive thyroid monitoring.